Literature DB >> 3953799

Interaction of flow and resistance in maintenance of portal hypertension in a rat model.

E Sikuler, R J Groszmann.   

Abstract

To clarify the roles that portocollateral resistance ("backward-flow" theory) and portal flow ("forward-flow" theory) play in maintaining chronic portal hypertension, we studied, in a rat model with prehepatic portal hypertension, the hemodynamic changes that occur when portocollateral resistance is reduced and high portal venous inflow is maintained. In 30 portal-hypertensive rats the constriction around the portal vein was removed 4 days after induction of portal hypertension, 30 rats were used as portal vein-constricted controls, and 30 additional rats were subjected to a sham operation. The removal of the ligature constricting the portal vein was followed by an immediate decrease in portal pressure (from 16.3 +/- 0.8 to 9.6 +/- 0.8 mmHg, P less than 0.001). Two days after the ligature removal, hyperdynamic circulation was still evident and was characterized by a decreased splanchnic arteriolar resistance and an increased portal venous inflow. The coexistence of high portal venous inflow and normal portal pressure indicates that high portal venous inflow per se is not sufficient to produce an increase in portal pressure when it faces a low-resistance vascular bed. We conclude that portal hypertension is induced by the interaction of an abnormally high portal venous inflow and high resistance offered to the flow by the portocollateral vessels. Neither the forward-flow theory nor the backward-flow theory can be applied solely to explain the increased portal pressure.

Entities:  

Mesh:

Year:  1986        PMID: 3953799     DOI: 10.1152/ajpgi.1986.250.2.G205

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  19 in total

Review 1.  Pathophysiology and epidemiology of portal hypertension.

Authors:  H Okumura; T Aramaki; Y Katsuta
Journal:  Drugs       Date:  1989       Impact factor: 9.546

2.  Postprandial changes in portal haemodynamics in patients with cirrhosis.

Authors:  S O'Brien; M Keogan; S Patchett; P A McCormick; N Afdhal; J E Hegarty
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

3.  [Spontaneous splenic rupture during portal triad clamping].

Authors:  S Baradaran; H J Mischinger; H Bacher; G Werkgartner; E Karpf; F G Linck
Journal:  Langenbecks Arch Chir       Date:  1995

Review 4.  Hepatic hemodynamic changes during liver transplantation: a review.

Authors:  An-Chieh Feng; Hsiu-Lung Fan; Teng-Wei Chen; Chung-Bao Hsieh
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

5.  Glucagon, stress, and portal hypertension. Plasma glucagon levels and portal hypertension in relation to anesthesia and surgical stress.

Authors:  T J Johnson; E M Quigley; T E Adrian; G Jin; L F Rikkers
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

6.  Gastric emptying of liquids and solids in the portal hypertensive rat.

Authors:  J A Reilly; C F Forst; E M Quigley; L F Rikkers
Journal:  Dig Dis Sci       Date:  1990-06       Impact factor: 3.199

7.  Abnormal splenic artery diameter/hepatic artery diameter ratio in cirrhosis-induced portal hypertension.

Authors:  Dao-Bing Zeng; Chuan-Zhou Dai; Shi-Chun Lu; Ning He; Wei Wang; Hong-Jun Li
Journal:  World J Gastroenterol       Date:  2013-02-28       Impact factor: 5.742

Review 8.  Pleiotropic effects of statins in the diseases of the liver.

Authors:  Martin Janicko; Sylvia Drazilova; Daniel Pella; Jan Fedacko; Peter Jarcuska
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

9.  Hemodynamic effects of hypothyroidism induced by methimazole in normal and portal hypertensive rats.

Authors:  R Oren; N Hilzenrat; Y Maaravi; A Yaari; E Sikuler
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

10.  Intrahepatic portal occlusion by microspheres: a new model of portal hypertension in the rat.

Authors:  V Jaffe; B Alexander; R T Mathie
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.